Opthea Share Price and Company Fundamentals
Last traded: 03/14/2025
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Key Metrics
PE ratio
-
PB ratio
-
Dividend yield
-
Beta
1.75
Market cap
$820.79M
Enterprise value
$937.34M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://opthea.com |
| Mailing address | Level 9 505 Little Collins Street Melbourne VIC 3000 Australia |
| Phone / Fax | 61 3 9826 0399 / 61 3 9824 0083 |
Dividends
More: Opthea Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Opthea paid $- dividend and the ex-dividend date was 11 Oct 2004.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.OPT dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Opthea.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | CEO & Chairperson | 72 | |
| Mr. Hamish George | CFO & Joint Company Secretary | ||
| Ms. Stephanie Vipond | Joint Company Secretary |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
2354933.20%
Return on assets
-79.28%
Return on equity
-
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Opthea is 820.79M and its enterprise value is 937.34M. The enterprise value to revenue ratio of OPT is 6420.14. The enterprise value to EBITDA ratio of OPT is -6.02.
The OPT's stocks Beta value is 1.75 making it 75% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Opthea (OPT)
Opthea (ASX:OPT) Frequently Asked Questions
1. What is Opthea's Stock Symbol?
Opthea trades on ASX under the ticker symbol "OPT".
2. What is Opthea's stock price today?
One share of OPT stock can currently be purchased for approximately $0.6.
3. How can I contact Opthea?
Opthea's mailing address is Level 9 505 Little Collins Street Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 9826 0399.
4. What is Opthea's official website?
The official website of Opthea is https://opthea.com.